{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:57:25Z","timestamp":1768323445321,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clinthera.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T19:56:36Z","timestamp":1569527796000},"page":"2204-2218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Celecoxib on the QTc Interval: A Thorough QT\/QTc Study"],"prefix":"10.1016","volume":"41","author":[{"given":"Seokuee","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeryeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Wook","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ryul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.09.004_bib1","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2165\/11208240-000000000-00000","article-title":"Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2019.09.004_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","article-title":"Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis","volume":"157","author":"Becker","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2019.09.004_bib3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1592\/phco.19.16.1269.30879","article-title":"Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib","volume":"19","author":"Zhao","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2019.09.004_bib4","first-page":"831","article-title":"Selective COX-2 inhibitors, NSAIDs and cardiovascular events\u2014is celecoxib the safest choice?","volume":"3","author":"Howes","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2019.09.004_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jcph.1302","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs and classical and selective cyclooxygenase-2 inhibitors: a meta-analysis of observational studies","volume":"59","author":"Martin Arias","year":"2019","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib6","first-page":"473","article-title":"Drug-induced QT prolongation and torsades de pointes","volume":"42","author":"Li","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.clinthera.2019.09.004_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.09.004_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1476-5381.2009.00207.x","article-title":"An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk","volume":"159","author":"Pollard","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026344","article-title":"Inhibition of HERG potassium channels by celecoxib and its mechanism","volume":"6","author":"Frolov","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2019.09.004_bib11","author":"US Food and Drug Administration"},{"key":"10.1016\/j.clinthera.2019.09.004_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2019.09.004_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/YIC.0000000000000124","article-title":"A\u00a0thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers","volume":"31","author":"Kim","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib14","first-page":"1233","article-title":"Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects","volume":"9","author":"Hong","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2019.09.004_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bcpt.12971","article-title":"Effects of Ojeok-san on the pharmacokinetics of celecoxib at steady-state in healthy volunteers","volume":"123","author":"Park","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/10543400801993002","article-title":"Sample size calculations in thorough QT studies","volume":"18","author":"Zhang","year":"2008","journal-title":"J\u00a0Biopharm Stat"},{"key":"10.1016\/j.clinthera.2019.09.004_bib17","first-page":"393","article-title":"Philips Medical Systems Support for Open ECG and Standardization Efforts","volume":"31","author":"Helfenbein","year":"2004","journal-title":"Comput Cardiol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jelectrocard.2012.01.007","article-title":"Semiautomated QT interval measurement in electrocardiograms from a thorough QT study: comparison of the grouped and ungrouped superimposed median beat methods","volume":"45","author":"Hingorani","year":"2012","journal-title":"J\u00a0Electrocardiol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1177\/0091270011419851","article-title":"Shortening of the QT interval after food can be used to demonstrate assay sensitivity in thorough QT studies","volume":"52","author":"Taubel","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00002018-200528110-00003","article-title":"Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead","volume":"28","author":"Shah","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2019.09.004_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A\u00a0new perspective in the field of cardiac safety testing through the comprehensive in\u00a0vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"J\u00a0Biomol Screen"},{"key":"10.1016\/j.clinthera.2019.09.004_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.12793\/tcp.2019.27.1.12","article-title":"Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative","volume":"27","author":"Park","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2125.2001.00340.x","article-title":"Frequency of cytochrome P450 2C9 mutant alleles in a Korean population","volume":"51","author":"Yoon","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00008571-200308000-00005","article-title":"Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2019.09.004_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12272-016-0861-2","article-title":"Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite","volume":"40","author":"Kim","year":"2017","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.clinthera.2019.09.004_bib27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0091270010381498","article-title":"Population pharmacokinetic and concentration\u2014QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies","volume":"51","author":"Florian","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.004_bib28","first-page":"690","article-title":"Sex differences in the evolution of the electrocardiographic QT interval with age","volume":"8","author":"Rautaharju","year":"1992","journal-title":"Can J Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:33Z","timestamp":1758963033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819304801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0149291819304801"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Celecoxib on the QTc Interval: A Thorough QT\/QTc Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}